Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. develops and commercializes biotechnology medicines for serious diseases across eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disease, neurological disease, hematologic conditions, infectious disease and rare disease. News about REGN commonly covers marketed products and pipeline programs such as EYLEA, EYLEA HD, Dupixent, Praluent, Libtayo, Kevzara, Otarmeni and investigational therapies developed through antibody, genetic medicine and RNA-based approaches.
Recurring company updates include financial results, FDA and European regulatory approvals, clinical trial data, label expansions, collaboration and licensing activity, product-access and pricing arrangements, share repurchase authorizations and corporate responsibility recognition. Regeneron's disclosures also frequently address its Sanofi collaboration around Dupixent and its use of proprietary technologies such as VelocImmune in drug discovery.
Regeneron and Sanofi (NASDAQ: REGN) announced a positive CHMP opinion recommending EU approval of Dupixent (dupilumab) to treat chronic spontaneous urticaria (CSU) in children aged 2–11 with inadequate response to H1 antihistamines and naive to anti-IgE therapy.
The opinion is supported by LIBERTY-CUPID Phase 3 data; a final EU decision is expected in coming months and a U.S. FDA decision is expected by April 2026.
Regeneron (NASDAQ: REGN) renews title sponsorship of the Regeneron Science Talent Search (STS) through 2036, pledging an additional $150 million and bringing its 20-year STS investment to $250 million. Combined STS and ISEF support totals more than $300 million from 2017–2036.
The renewal continues funding for STEM outreach, cites a 49% increase in STS entries since 2017, and notes engagement of over 20,000 students and recognition of 3,000 Regeneron scholars.
Regeneron (NASDAQ: REGN) and Sanofi announced FDA approval of Dupixent (dupilumab) on Feb 24, 2026 for treating allergic fungal rhinosinusitis (AFRS) in adults and children aged 6+ with a history of sino-nasal surgery.
Approval was based on a Phase 3 trial showing marked reductions in sinus opacification, nasal symptoms, polyp size, and a 92% reduction in risk of systemic corticosteroid use or surgery over 52 weeks.
Regeneron (NASDAQ: REGN) announced the FDA has accepted the Biologics License Application for garetosmab for adults with fibrodysplasia ossificans progressiva (FOP) and granted Priority Review with a target action date in August 2026.
The BLA is supported by positive Phase 3 OPTIMA results showing large reductions in new heterotopic bone lesions and volume versus placebo, and a safety profile with common adverse reactions including epistaxis and increased hair growth.
Regeneron (NASDAQ: REGN) will webcast management presentations at two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 9:10 a.m. ET and Leerink Partners 2026 Global Healthcare Conference on March 11, 2026 at 10:40 a.m. ET.
According to the company, sessions are accessible via its Investors & Media page, with replays and transcripts archived on the website for at least 30 days.
Regeneron (NASDAQ: REGN) will present 36 abstracts at AAAAI 2026 (Feb 27–Mar 2), including first Phase 3 allergen-challenge results for investigational antibody cocktails targeting cat (Fel d 1) and birch (Bet v 1) allergies and multiple new Dupixent® (dupilumab) analyses across pediatric allergy sensitization, asthma, CRSwNP and EoE.
Regeneron said additional registration-enabling trials for the cat and birch programs will start in 2026, and a Dupixent supplemental BLA for AFRS is under Priority Review with a target action date of Feb 28, 2026.
Regeneron (NASDAQ: REGN) will present new clinical data for EYLEA HD (aflibercept) 8 mg at the virtual Angiogenesis meeting on February 7, 2026. Presentations include final 64-week QUASAR results in retinal vein occlusion (RVO) and full primary Phase 3b ELARA data for monthly dosing.
FDA recently approved EYLEA HD for macular edema following RVO; QUASAR met its 36-week primary endpoint and offers the first every-two-month treatment option versus prior monthly dosing. ELARA supports a monthly option for patients needing more frequent treatment. Common adverse reactions (≥3%) are listed in the safety data.
Regeneron (NASDAQ: REGN) reported Q4 2025 revenues of $3.884B (up 3% YoY) and full-year 2025 revenues of $14.343B (up 1% YoY). Q4 GAAP EPS was $7.86 and non-GAAP EPS was $11.44. Key commercial drivers included strong Dupixent and EYLEA HD performance and increased Sanofi collaboration revenue.
Regeneron secured multiple regulatory approvals for EYLEA HD, Dupixent and Libtayo and filed BLAs/NDAs for programs including DB-OTO and garetosmab. The company plans substantial manufacturing and R&D investments in 2026.
Regeneron (NASDAQ: REGN) and Society for Science named the top 40 finalists for the Regeneron Science Talent Search 2026, representing 35 schools across 15 states and competing for more than $1.8 million in awards, including a $250,000 top prize. Finalists were selected from 300 scholars and more than 2,600 entrants based on original research. Finalists will compete March 5-11, 2026, with a public project exhibition on March 8 and winners announced March 10 in Washington, D.C. Regeneron noted its 10-year $100 million commitment and an expanded annual award distribution now totaling $3.1 million.
Regeneron (NASDAQ: REGN) will report fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, released before U.S. markets open.
The company will host a conference call and simultaneous webcast on January 30, 2026 at 8:30 AM Eastern Time. Investors may join the live webcast via Regeneron’s Investors and Media web page or register in advance to participate by telephone and receive dial-in details, a unique passcode, and registrant ID.
A replay and transcript will be archived on the company website for at least 30 days.